NASDAQ:KRYS
Krystal Biotech, Inc.
Krystal Biotech, Inc.'s revenue grew 33.9% in fiscal 2025 to $389.1M while operating margin rose to 41.5%, its highest in 3 years. Free cash flow was $188.9M, 48.5% of revenue, and the diluted share count rose 0.7%.Summary generated from Krystal Biotech, Inc.'s SEC filings. Latest annual report filed Feb 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$389.1M
Revenue growth+33.9%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin41.5%
Net margin52.6%
ROICn/a
Return on equity18.9%
Debt / equityn/a
Free cash flow$188.9M
FCF margin48.5%
Share count change+0.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 51 | 291 | 389 |
| Operating income | −68 | −145 | −110 | 66 | 161 |
| Net income | −70 | −140 | 11 | 89 | 205 |
| Free cash flow | −116 | −154 | −101 | 119 | 189 |
Recent filings
- 4Insider transaction report
Sep 16, 2026 - 4Insider transaction report
Sep 16, 2026 - 8-KResults of operations and financial condition
Aug 3, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 3, 2026 - 8-KOther events
Jul 21, 2026 - 8-KResults of a shareholder vote
May 20, 2026 - 8-KCurrent report
May 4, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 4, 2026